Intelligent Medicine Acquisition Stock EBITDA

Intelligent Medicine Acquisition fundamentals help investors to digest information that contributes to Intelligent Medicine's financial success or failures. It also enables traders to predict the movement of Intelligent Stock. The fundamental analysis module provides a way to measure Intelligent Medicine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intelligent Medicine stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Intelligent Medicine Acquisition Company EBITDA Analysis

Intelligent Medicine's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Intelligent Medicine EBITDA

    
  (14.54 M)  
Most of Intelligent Medicine's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intelligent Medicine Acquisition is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Intelligent Medicine Acquisition reported earnings before interest,tax, depreciation and amortization of (14.54 Million). This is 100.02% lower than that of the Financial Services sector and significantly lower than that of the Shell Companies industry. The ebitda for all United States stocks is 100.37% higher than that of the company.

Intelligent EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intelligent Medicine's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intelligent Medicine could also be used in its relative valuation, which is a method of valuing Intelligent Medicine by comparing valuation metrics of similar companies.
Intelligent Medicine is currently under evaluation in ebitda category among its peers.

Intelligent Fundamentals

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Consideration for investing in Intelligent Stock

If you are still planning to invest in Intelligent Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intelligent Medicine's history and understand the potential risks before investing.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Equity Valuation
Check real value of public entities based on technical and fundamental data